RG002C0106

DRUG3 trials

Sponsors

Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.

Conditions

IgA Nephropathy (IgAN)Renal ImpairmentsSafety Issues

Phase 1

A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults

Active, not recruitingNCT06494527

Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.Safety Issues

Start: 2024-10-18End: 2026-08-20Target: 30Updated: 2026-03-03

A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment

Not yet recruitingNCT07445906

Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.IgA Nephropathy (IgAN), Renal Impairments

Start: 2026-03-15End: 2026-12-01Target: 24Updated: 2026-03-03

Phase 2

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

RecruitingNCT07305974

Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.IgA Nephropathy (IgAN)

Start: 2025-09-08End: 2029-03-31Target: 30Updated: 2025-12-26